Kim MS, Jin YJ, Lee JW, Lee JI, Kim YS, Lee SY, Chae MH. Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report. World J Gastrointest Oncol 2013; 5(2): 38-42 [PMID: 23556056 DOI: 10.4251/wjgo.v5.i2.38]
Corresponding Author of This Article
Jin-Woo Lee, MD, PhD, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, 7-206, 3-Ga, Shinheung-Dong, Jung-Gu, Incheon 400-711, South Korea. email@example.com
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Feb 15, 2013; 5(2): 38-42 Published online Feb 15, 2013. doi: 10.4251/wjgo.v5.i2.38
Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report
Min Su Kim, Young-Joo Jin, Jin-Woo Lee, Jung-il Lee, Young Soo Kim, Sun Young Lee, Myoung Hun Chae
Min Su Kim, Young-Joo Jin, Jin-Woo Lee, Jung-il Lee, Myoung Hun Chae, Young soo Kim, Sun young Lee, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon 400-711, South Korea
Author contributions: Kim MS, Jin YJ and Lee JW made contributions to the conception and design, collection and assembly, analysis and interpretation of the data, drafting of the article, provision of study materials or patients, administrative and technical or logistic support; Lee JI and Kim YS made contributions to provision of study materials or patients and drafting of the article; Lee SY and Chae MH collected and assembed the data and provided the study materials or patients.
Supported by Inha University Research Grant
Correspondence to: Jin-Woo Lee, MD, PhD, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, 7-206, 3-Ga, Shinheung-Dong, Jung-Gu, Incheon 400-711, South Korea. firstname.lastname@example.org
Telephone: +82-32-8902548 Fax: +82-32-8902549
Received: December 3, 2012 Revised: January 3, 2013 Accepted: January 18, 2013 Published online: February 15, 2013
Hepatocellular carcinoma (HCC) is the fifth most common malignant disease worldwide, and curative treatment remains difficult because the majority of cases are diagnosed in the advanced stage. Sorafenib is the only known effective systemic treatment, but patients rarely achieve complete remission (CR). A 66-year-old man with a history of alcoholic liver cirrhosis with a diagnosis of advanced HCC, was initially treated with transarterial chemoembolization on four occasions. However, the disease progressed with portal vein thrombosis. Therefore, sorafenib was started, and 4 mo later, the patient achieved CR. The treatment was continued for 12 mo, and CR was maintained up to 4 mo after sorafenib discontinuation.